Akili, Inc. is a digital medicine company, which engages in the development of cognitive treatments through technologies. Its technologies are designed to directly target the physiology of the brain. The company was founded by W. Edward Martucci II and Adam Gazzaley in December 2020 and is headquartered in Boston, MA.
Sector:
Health Technology
Industry:
Medical Specialties
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Akili Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Akili Inc market cap is $34.01M.
What is the 52-week high for Akili Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Akili Inc 52 week high is $1.25 as of September 18, 2025.
What is the 52-week low for Akili Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Akili Inc 52 week low is $0.1912 as of September 18, 2025.
What is Akili Inc stock price today?
Akili Inc stock price today is $0.44.
What was Akili Inc stock price yesterday?
Akili Inc stock price yesterday was $0.4347.
What is the PE ratio of Akili Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Akili Inc’s P/E ratio is -0.70.
What is the Price-to-Book ratio of Akili Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Akili Inc P/B ratio is 0.6770.
What is the 50-day moving average of Akili Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Akili Inc 50-day moving average is $0.4237.
